AYTU BIOPHARMA, INC Debt Instrument, Unamortized Discount (Premium), Net
AYTU BIOPHARMA, INC (AYTU) had Debt Instrument, Unamortized Discount (Premium), Net of $519.00 thousand as of 2024-03-31, per its 10-Q filed 2024-05-15.
Discontinued › Notes › Debt › Debt Instrument, Unamortized Discount (Premium), Net
us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet · last filed 2024-05-15
- 2024-03-31: Debt Instrument, Unamortized Discount (Premium), Net $519.00K.
- 2023-12-31: Debt Instrument, Unamortized Discount (Premium), Net $660.00K.
- 2023-06-30: Debt Instrument, Unamortized Discount (Premium), Net $925.00K.
| Period end | Debt Instrument, Unamortized Discount (Premium), Net |
|---|---|
| 2024-03-31 | $519.00K 10-Q · filed 2024-05-15 |
| 2023-12-31 | $660.00K 10-Q · filed 2024-02-14 |
| 2023-06-30 | $925.00K 10-Q · filed 2024-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |